natgillin/translations-raw huggingface dataset:
Concomitant administration of
Pri sočasni uporabi boceprevirja
Concomitant administration of
Sočasna uporaba rivaroksabana in
Concomitant administration of
Sočasni uporabi
Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range.
Pri bolnikih, ki so v kliničnih preskušanjih hkrati dobivali 40 mg esomeprazola in varfarin, so ugotovili koagulacijske čase v sprejemljivem razponu.
Concomitant administration of 90 mg ticagrelor BID (maintenance dose) with 110 mg dabigatran etexilate increased the adjusted dabigatran AUCτ,ss and Cmax,ss 1.26-fold and 1.29-fold, respectively, compared with dabigatran etexilate given alone.
Pri hkratnem dajanju odmerka po 90 mg ticagrelorja dvakrat na dan (vzdrževalni odmerek) in odmerka po 110 mg dabigatran eteksilata sta se prilagojeni AUCτ,ss in Cmax,ss v primerjavi z dajanjem samega dabigatrana povečali za 1,26-krat in 1,29-krat.
Concomitant administration of a loading dose of 180 mg ticagrelor and 110 mg dabigatran etexilate (in steady state) increased the dabigatran AUCτ,ss and Cmax,ss by 1.49-fold and 1.65-fold (+49% and 65%), respectively, compared with dabigatran etexilate given alone.
Pri hkratnem dajanju polnilnega odmerka po 180 mg ticagrelorja in odmerka dabigatran eteksilata po 110 mg (v stanju dinamičnega ravnovesja) sta se AUCτ,ss in Cmax,ss dabigatrana v primerjavi z dajanjem samega dabigatran eteksilata povečali, in sicer za 1,49-krat oziroma 1,65-krat (+49 % in 65
Concomitant administration of a P-gp inducer (such as rifampicin, St. John´s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran concentrations and should be avoided (see sections 4.4 and 5.2).
Sočasno dajanje induktorja P-gp (na primer rifampicina, šentjanževke (Hypericum perforatum), karbamazepina ali fenitoina) predvidoma zmanjša dabigatranovo koncentracijo, zato se ga moramo izogibati (glejte poglavji 4.4 in 5.2).
Concomitant administration of a P-gp inducer (such as rifampicin, St. John´s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran concentrations and should be avoided (see sections 4.4 and 5.2).
Sočasno dajanje induktorja P-gp (na primer rifampicina, šentjanževke (Hypericum perforatum), karbamazepina, fenitoina) predvidoma zmanjša dabigatranovo koncentracijo, zato se ga moramo izogibati (glejte poglavji 4.4 in 5.2).
Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. (See section 4.5).
Sočasna uporaba adalimumaba z drugimi biološkimi DMARDS (t.j.anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. (See section 4.5).
Sočasna uporaba adalimumaba z drugimi biološkimi DMARDS (t.j.anakinra in abacept) ali z drugimi antagonisti TNF ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami, in drugih potencialnih farmakoloških interakcij (glejte poglavje 4.5).
Concomitant administration of amiodarone, verapamil, amlodipine or diltiazem (see section 4.5)
Sočasno zdravljenje z amiodaronom, verapamilom, amlodipinom ali diltiazemom (glejte poglavje 4.5)
Concomitant administration of antipsychotics with dopamine receptor-blocking properties, particularly D2 receptor antagonists should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.
Sočasno dajanje antipsihotikov, ki delujejo kot zaviralci dopaminskih receptorjev, zlasti pa antagonistov receptorjev D2, zahteva previdnost, bolnika pa je treba skrbno spremljati, če bi prišlo do izgube antiparkinsonskega učinka ali poslabšanja parkinsonskih simptomov.
Concomitant administration of Aptivus, co-administered with low dose ritonavir, and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Sočasnega dajanja zdravilaAptivus, ob hkratnih majhnih odmerkih ritonavirja, in the glukokortikosteroidov, razen kadar je možna korist zdravljenja večja od tveganja sistemskih kortikosteroidnih učinkov (glejte poglavje 4.4), ne priporočamo.
Concomitant administration of boosted PREZISTA and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Sočasna uporaba okrepljenega zdravila PREZISTA in teh glukokortikoidov ni priporočljiva, razen če morebitna korist zdravljenja odtehta tveganje, ki ga predstavljajo sistemski učinki kortikosteroidov.
Concomitant administration of boosted PREZISTA with ticagrelor is contraindicated.
Sočasna uporaba okrepljenega zdravila PREZISTA in tikagrelorja je kontraindicirana.
Concomitant administration of boosted saquinavir and fluticasone propionate and other corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
flutikazonproprionata s sakvinavirjem s podporno terapijo in drugih kortikosteroidov, ki se presnavljajo s P450 3A (npr. budenozid), ne priporočamo, razen v primerih, ko možne koristi zdravljenja prevladajo nad tveganjem za pojav sistemskih kortikosteroidnih učinkov (glejte poglavje 4.4).
Concomitant administration of DepoCyte with other antineoplastic agents administered by the intrathecal route has not been studied.
Skupne uporabe zdravila DepoCyte in drugih zdravil, ki delujejo na novotvorbe in so uporabljena po intratekalni poti, niso raziskovali.
Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result in several-fold increased plasma concentrations of aprepitant (see section 4.4).
Pri sočasni uporabi zdravila EMEND in zdravilnih učinkovin, ki zavirajo aktivnost CYP3A4 (npr. ketokonazol, itrakonazol, vorikonazol, posakonazol, klaritromicin, telitromicin, nefazodon in zaviralci proteaz) je potrebna previdnost, ker se zaradi kombinacije pričakuje večkratno zvišanje plazemskih koncentracij aprepitanta (glejte poglavje 4.4).
Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result several-fold in increased plasma concentrations of aprepitant (see section 4.4).
Pri sočasni uporabi zdravila EMEND in zdravilnih učinkovin, ki zavirajo aktivnost CYP3A4 (npr. ketokonazol, itrakonazol, vorikonazol, posakonazol, klaritromicin, telitromicin, nefazodon in zaviralci proteaz) je potrebna previdnost, ker se zaradi kombinacije pričakuje večkratno zvišanje plazemskih koncentracij aprepitanta (glejte poglavje 4.4).
Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy of EMEND.
Sočasnemu dajanju zdravila EMEND in zdravilnih učinkovin, ki močno inducirajo aktivnost CYP3A4 (npr. rifampicin, fenitoin, karbamazepin, fenobarbital), se je treba izogibati, saj se pri kombiniranju zmanjšajo plazemske koncentracije aprepitanta, zaradi česar se lahko zmanjša učinkovitost zdravila
Concomitant administration of EMEND with herbal preparations containing St. John’s Wort (Hypericum perforatum) is not recommended.
Sočasno uporabo zdravila EMEND in pripravkov rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), odsvetujemo.
Concomitant administration of Enurev Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Sočasna uporaba zdravila Enurev Breezhaler in peroralno inhaliranega indakaterola, agonista adrenergičnih receptorjev beta-2, v stanju dinamičnega ravnovesja obeh učinkovin ni vplivala na njuno farmakokinetiko.
Concomitant administration of erythropoietic agents or previous history of DVT may also increase thrombotic risk in these patients.
Sočasna uporaba eritropoetskih zdravil ali globoka venska tromboza v anamnezi lahko pri teh bolnikih tudi povečata tveganje za trombozo.
Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP 3A4 may result in more than doubling of the esomeprazole exposure.
Sočasna uporaba esomeprazola in kakšnega kombiniranega zaviralca CYP2C19 in CYP3A4 lahko več kot podvoji izpostavljenost esomeprazolu.
Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice a day (b.i.d.)), resulted in a doubling of the exposure (AUC) to esomeprazole.
Sočasna uporaba esomeprazola in zaviralca CYP3A4, klaritromicina (500 mg dvakrat na dan) je podvojila izpostavljenosti (AUC) esomeprazolu.
Concomitant administration of fibrates, statins, danazol, ciclosporin or potent cytochrome P450 (CYP) 3A4 inhibitors (see section 4.5)
Sočasna uporaba fibratov, statinov, danazola, ciklosporina ali močnih zaviralcev citokroma P450 (CYP) 3A4 (glejte poglavje 4.5)
Concomitant administration of fosaprepitant with herbal preparations containing St. John’s Wort (Hypericum perforatum) is not recommended.
Sočasne uporabe fosaprepitanta in pripravkov rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), ne priporočamo.
Concomitant administration of gefitinib with ranitidine at a dose that caused sustained elevations in gastric pH ≥5 resulted in a reduced mean gefitinib AUC by 47% in healthy volunteers (see section 4.4 and 5.2).
Sočasna uporaba gefitiniba z ranitidinom v odmerku, ki je dolgotrajno zvišal pH v želodcu ≥ 5, je pri zdravih prostovoljcih zmanjšala povprečno AUC gefitiniba za 47 % (glejte poglavji 4.4 in 5.2).
Concomitant administration of higher doses than 100 mg ASA should only be performed under medical supervision.
Sočasna uporaba odmerkov ASA, večjih od 100 mg, je dovoljena samo pod medicinskih nadzorom.
Concomitant administration of hydrochlorothiazide and irbesartan has no effect on the pharmacokinetics of either medicinal product.
Farmakokinetične lastnosti posameznih učinkovin se med njuno hkratno uporabo ne spremenijo.
Concomitant administration of inhibitors of P-gp, e.g. cyclosporine and verapamil, may alter trabectedin distribution and/or elimination.
Hkratno dajanje zaviralcev P-gp, npr. ciklosporina in verapamila lahko spremenijo porazdelitev in/ali izločanje trabektedina.
Concomitant administration of Invirase and quetiapine is contra- indicated as it may increase quetiapine-related toxicity.
Zaradi možnega povečanja s kvetiapinom povezane toksičnosti je sočasna uporaba zdravila Invirase in kvetiapina kontraindicirana.
Concomitant administration of IXIARO with inactivated hepatitis A vaccine and with inactivated rabies vaccine in two different schedules has been evaluated in clinical studies.
Hkratno odmerjanje cepiva IXIARO z deaktiviranim cepivom proti hepatitisu A in deaktiviranim cepivom proti steklini po dveh različnih urnikih je bilo ocenjeno v kliničnih študijah.
Concomitant administration of IXIARO with inactivated hepatitis A virus (HAV) vaccine (HAVRIX 1440) The concomitant use of IXIARO with inactivated hepatitis A virus (HAV) vaccine (HAVRIX 1440) has been explored in one clinical trial.
Hkratno odmerjanje cepiva IXIARO z deaktiviranim cepivom proti hepatitisu A (HAVRIX 1440) Sočasno uporabo cepiva IXIARO s cepivom z inaktiviranimi virusi hepatitisa A (HAVRIX 1440) so raziskali v enem kliničnem preskušanju.
Concomitant administration of IXIARO with inactivated rabies vaccine (Rabipur):
Hkratno odmerjanje cepiva IXIARO z deaktiviranim cepivom proti steklini (Rabipur):
Concomitant administration of IXIARO with other vaccines:
Hkratno odmerjanje cepiva IXIARO z drugimi cepivi:
Concomitant administration of Kaletra and alfuzosin is contra- indicated (see section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased.
Sočasna uporaba zdravila Kaletra in alfuzosina je kontraindicirana (glejte poglavje 4.3), ker se lahko poveča z alfuzosinom povezana toksičnost, vključno s hipotenzijo.
Concomitant administration of Kaletra and amiodarone or dronedarone is contraindicated (see section 4.3) as the risk of arrhythmias or other serious adverse reactions may be increased.
Sočasna uporaba zdravila Kaletra in amiodarona ali dronedarona je kontraindicirana (glejte poglavje 4.3), ker se lahko poveča tveganje za aritmije ali druge resne neželene učinke.
Concomitant administration of Kaletra and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Sočasna uporaba zdravila Kaletra in kvetiapina je kontraindicirana, ker lahko poveča toksičnost, povezano s kvetiapinom.
Concomitant administration of Kaletra with fusidic acid is contra-indicated in dermatological indications due to the increased risk of adverse events related to fusidic acid, notably rhabdomyolysis (see section 4.3).
Sočasna uporaba zdravila Kaletra s fusidno kislino je kontraindicirana pri dermatoloških indikacijah, ker obstaja večje tveganje za neželene učinke, povezane s fusidno kislino, zlasti za rabdomiolizo (glejte poglavje 4.3).
Concomitant administration of Ketek and colchicine in patients with renal and/or hepatic impairment (see section 4.5).
Sočasno jemanje zdravila Ketek in kolhicina pri bolnikih z okvaro ledvic in/ali jeter (glejte poglavje 4.5).
Concomitant administration of Ketek and colchicine is contraindicated in patients with renal and/or hepatic impairment (see section 4.3).
Sočasna uporaba zdravila Ketek in kolhicina je kontraindicirana pri bolnikih z okvaro ledvic in/ali jeter (glejte poglavje 4.3).
Concomitant administration of moderate CYP3A4 inhibitors (see sections 4.2 and 4.5).
Sočasna uporaba zmernih zaviralcev CYP3A4 (glejte poglavji 4.2 in 4.5).
Concomitant administration of nelarabine in combination with adenosine deaminase inhibitors, such as pentostatin is not recommended.
Sočasne uporabe nelarabina in zaviralcev adenozin-deaminaze, kot je pentostatin, ne priporočamo.
Concomitant administration of Norvir and quetiapine is contraindicated as it may increase quetiapine-related toxicity (see section 4.3).
Sočasna uporaba zdravila Norvir in kvetiapina je kontraindicirana, ker lahko poveča toksičnost, povezano s kvetiapinom (glejte poglavje 4.3).
Concomitant administration of Norvir and quetiapine is contraindicated as it may increase quetiapine-related toxicity (see section 4.3).
Sočasna uporaba zdravila Norvir in kvetiapina je kontraindicirana, ker se lahko poveča toksičnost, povezana s kvetiapinom (glejte poglavje 4.3).
Concomitant administration of orally inhaled indacaterol and glycopyrronium, under steady-state conditions of both components, did not affect the pharmacokinetics of either component.
Sočasna uporaba peroralno inhaliranih indakaterola in glikopironija v stanju dinamičnega ravnovesja obeh učinkovin ni vplivala na farmakokinetične lastnosti niti prve niti druge od obeh učinkovin.
Concomitant administration of other sympathomimetic agents (alone or as part of combination therapy) may potentiate the adverse events of indacaterol (see section 4.4).
Sočasna uporaba drugih simpatikomimetičnih zdravil (samih ali v sklopu kombinacije zdravil) lahko okrepi neželene učinke indakaterola (glejte poglavje 4.4).
Concomitant administration of P-gp inducers (such as rifampicin, St. John`s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).
Pri sočasnem dajanju induktorjev P-gp, kot so rifampicin, šentjanževka (Hypericum perforatum), karbamazepin ali fenitoin, se zmanjša koncentracija dabigatrana v plazmiin se jih je treba izogibati (glejte poglavji 4.5 in 5.2).
Concomitant administration of P-gp inducers (such as rifampicin, St. John`s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).
Sočasno jemanje dabigatran eteksilata in induktorjev P-gp (kot so rifampicin, šentjanževka (Hypericum perforatum), karbamazepin ali fenitoin) predvidoma zmanjša koncentracijo dabigatrana v plazmi in se jih je treba izogibati (glejte poglavji 4.5 in 5.2).
Concomitant administration of P-gp inducers (such as rifampicin, St. John`s wort (Hypericum perforatum), carbamazepine, or phenytoin) is expected to result in decreased dabigatran plasma concentrations, and should be avoided (see sections 4.5 and 5.2).
Sočasno jemanje induktorjev P-gp (kot so rifampicin, šentjanževka (Hypericum perforatum), karbamazepin ali fenitoin) predvidoma zmanjša koncentracijo dabigatrana v plazmi in se jim je treba izogibati (glejte poglavji 4.5 in 5.2).
Concomitant administration of P-gp inhibitors (see sections 4.2 and 4.5).
Sočasna uporaba zaviralcev P-gp (glejte poglavji 4.2 in 4.5).
Concomitant administration of P-gp inhibitors (such as amiodarone, verapamil, quinidine, ketoconazole, dronedarone, clarithromycin and ticagrelor) is expected to result in increased dabigatran plasma concentrations.
Sočasno dajanje zaviralcev P-gp (kot so amiodaron, verapamil, kinidin, ketokonazol, dronedaron, klaritromicin in ticagrelor) predvidoma poveča koncentracijo dabigatrana v plazmi.
Concomitant administration of P-gp inhibitors such as ciclosporin and verapamil may have the potential to increase plasma concentrations of cobimetinib.
Sočasna uporaba zaviralcev P-gp, npr. ciklosporina in verapamila, lahko zviša koncentracijo kobimetiniba v plazmi.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).
Sočasna uporaba pioglitazon z gemfibrozilom (zaviralec citokroma P450 2C8) oz. rifampicina (induktor citokroma P450 2C8) je povečala (gemfibrozil) oz. zmanjšala (rifampicin) koncentracijo pioglitazona v plazmi (glejte poglavje 4.5).
Concomitant administration of Possia increased the digoxin Cmax by 75% and AUC by 28%.
Sočasna uporaba zdravila Possia je povečala Cmax digoksina za 75 % in njegovo AUC za 28 %.
Concomitant administration of potent inducers of P-gp, glucuronidation, and/or CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or St John’s Wort [Hypericum perforatum]) may lead to suboptimal exposure to vemurafenib and should be avoided.
Sočasna uporaba močnih induktorjev P-gp, glukuronidacije in/ali CYP3A4 (npr. rifampicina, rifabutina, karbamazepina, fenitoina ali šentjanževke [Hypericum perforatum]) lahko vodi v suboptimalno izpostavljenost vemurafenibu in se ji je treba izogibati.
Concomitant administration of potent inducers of P-gp, glucuronidation, CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or St John’s Wort [hypericin]) should be avoided when possible (see section 4.5).
Sočasnemu dajanju močnih induktorjev P-gp, glukuronidacije, CYP3A4 (npr. rifampicina, rifabutina, karbamazepina, fenitoina ali šenjanževke [hipericin]) se je treba izogibati, kadar je to mogoče (glejte poglavje 4.5).
Concomitant administration of PREZISTA co-administered with low dose ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Sočasna uporaba zdravila PREZISTA z majhnim odmerkom ritonavirja in teh glukokortikoidov ni priporočljiva, razen če morebitna korist zdravljenja odtehta tveganje, ki ga predstavljajo sistemski učinki kortikosteroidov.
Concomitant administration of PREZISTA with low dose ritonavir and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Sočasna uporaba zdravila PREZISTA skupaj z majhnim odmerkom ritonavirja in s kvetiapinom je kontraindicirana, ker lahko zveča s kvetiapinom povezano toksičnost.
Concomitant administration of PREZISTA with low dose ritonavir with ticagrelor is contraindicated.
Sočasna uporaba zdravila PREZISTA skupaj z majhnim odmerkom ritonavirja in tikagrelorjem je kontraindicirana.
Concomitant administration of rasagiline and entacapone increased rasagiline oral clearance by 28%.
Sočasna uporaba razagilina in entakapona poveča oralni očistek razagilina za 28 %.
Concomitant administration of Seebri Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Sočasna uporaba zdravila Seebri Breezhaler in peroralno inhaliranega indakaterola, agonista adrenergičnih receptorjev beta-2, v stanju dinamičnega ravnovesja obeh učinkovin ni vplivala na njuno farmakokinetiko.
Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum) (see section 4.5).
Sočasna uporaba močnih zaviralcev CYP3A4 (npr. boceprevir, klaritromicin, kobicistat, indinavir, itrakonazol, ketokonazol, nefazodon, nelfinavir, posakonazol, ritonavir, sakvinavir, telaprevir, telitromicin, vorikonazol) in močnih induktorjev CYP3A4 (npr. karbamazepin, fenobarbital, fenitoin, rifampicin, šentjanževka (Hypericum perforatum) (glejte poglavje 4.5).
Concomitant administration of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin) may inhibit the metabolism of, and increase the systemic exposure to, vilanterol.
Sočasna uporaba močnih zaviralcev CYP3A4 (npr. ketokonazola, klaritromicina, itrakonazola, ritonavirja, telitromicina) lahko zavre presnovo vilanterola in poveča sistemsko izpostavljenost temu zdravilu.
Concomitant administration of sunitinib with potent CYP3A4 inhibitors should be limited because of the possible increase in sunitinib plasma concentrations (see sections 4.2 and 4.5).
Sočasna uporaba sunitiniba z močnimi zaviralci CYP3A4 mora biti omejena zaradi možnega zvečanja koncentracije sunitiniba v plazmi (glejte poglavji 4.2 in 4.5).
Concomitant administration of these medicinal products is not recommended.
Med sočasno uporabo z zdavilom
Concomitant administration of these medicinal products is not recommended.
odmerkov fosamprenavirja (1400 mg
Concomitant administration of these medicinal products is not recommended.
Sočasna uporaba teh zdravil ni
Concomitant administration of ticagrelor increased the digoxin Cmax by 75% and AUC by 28%.
Sočasna uporaba ticagrelorja je povečala Cmax digoksina za 75 % in njegovo AUC za 28 %.
Concomitant administration of tipranavir, co-administered with low dose ritonavir, with saquinavir/ritonavir, is not recommended.
Sočasnega dajanja tipranavirja z nizkimi odmerki ritonavirja, in sakvinavirja/ritonavirja se ne priporoča.